Desvaleryl Valsartan | CAS#676129-92-3 | Potential impurity in preparations of AT1 receptor antagonist valsartan

MedKoo Cat#: 112019 | Name: Desvaleryl Valsartan

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desvaleryl valsartan is a potential impurity found in commercial preparations of the angiotensin II type 1 (AT1) receptor antagonist valsartan. It is a degradation product formed under acidic conditions.

Chemical Structure

Desvaleryl Valsartan

CAS#676129-92-3

Theoretical Analysis

MedKoo Cat#: 112019

Name: Desvaleryl Valsartan

CAS#: 676129-92-3

Chemical Formula: C19H21N5O2

Exact Mass: 351.1695

Molecular Weight: 351.41

Elemental Analysis: C, 64.94; H, 6.02; N, 19.93; O, 9.11

Price and Availability

Size	Price	Availability
10mg	USD 365.00	2 Weeks
25mg	USD 685.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Valsartan Impurity B; Desoxopentyl valsartan; Desvaleryl Valsartan

IUPAC/Chemical Name

((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-L-valine

InChi Key

NSXSCTCKWRSTHJ-KRWDZBQOSA-N

InChi Code

InChI=1S/C19H21N5O2/c1-12(2)17(19(25)26)20-11-13-7-9-14(10-8-13)15-5-3-4-6-16(15)18-21-23-24-22-18/h3-10,12,17,20H,11H2,1-2H3,(H,25,26)(H,21,22,23,24)/t17-/m0/s1

SMILES Code

CC([C@H](NCC1=CC=C(C2=C(C=CC=C2)C3=NN=NN3)C=C1)C(O)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMF	3.0	8.54
	DMSO	5.0	14.23
	Ethanol	1.0	2.85

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 351.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Monosilio S, Filomena D, Luongo F, Sannino M, Cimino S, Neccia M, Mariani MV, Birtolo LI, Benedetti G, Tonti G, Pedrizzetti G, Vizza CD, Maestrini V, Agati L. Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis. Front Cardiovasc Med. 2022 May 18;9:883769. doi: 10.3389/fcvm.2022.883769. PMID: 35665260; PMCID: PMC9157573. 2: Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio- oncology. Adv Pharmacol. 2022;94:365-409. doi: 10.1016/bs.apha.2022.02.002. Epub 2022 Mar 30. PMID: 35659376. 3: Nguyen TTL, Wang M, Liu D, Iyer S, Gonzalez Bonilla HM, Acker N, Murthy V, Shrivastava S, Desai V, Burnett JC Jr, Redfield M, Bailey KR, Weinshilboum RM, Pereira NL. Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences. Circ Heart Fail. 2022 Jun 3:101161CIRCHEARTFAILURE122009629. doi: 10.1161/CIRCHEARTFAILURE.122.009629. Epub ahead of print. PMID: 35656806. 4: Curtain JP, Campbell RT, Petrie MC, Jackson AM, Abraham WT, Desai AS, Dickstein K, Køber L, Rouleau JL, Swedberg K, Zile MR, Solomon SD, Jhund PS, McMurray JJV. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC Heart Fail. 2022 Jun;10(6):415-427. doi: 10.1016/j.jchf.2022.01.020. Epub 2022 Apr 6. PMID: 35654526. 5: Jackson AM, Benson L, Savarese G, Hage C, Jhund PS, Petrie MC, Dahlström U, McMurray JJV, Lund LH. Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006. PMID: 35654522. 6: Msungu SD, Mushongi AA, Venkataramana PB, Mbega ER. Status of carotenoids in elite and landrace maize genotypes: Implications for provitamin A biofortification in Tanzania. Food Res Int. 2022 Jun;156:111303. doi: 10.1016/j.foodres.2022.111303. Epub 2022 May 7. PMID: 35651063. 7: Zuo C, Li X, Fan L, Li J, Tian D, Chen C, Li X, Lv Q. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. J Clin Pharm Ther. 2022 Jun 1. doi: 10.1111/jcpt.13699. Epub ahead of print. PMID: 35649528. 8: Be Rziņš KR, Fraser-Miller SJ, Rades T, Gordon KC. Low-Frequency Raman Spectroscopy as an Avenue to Determine the Transition Temperature of β- and γ-Relaxation in Pharmaceutical Glasses. Anal Chem. 2022 Jun 1. doi: 10.1021/acs.analchem.2c00371. Epub ahead of print. PMID: 35647784. 9: Ding Y, Wei Z, Li J, Zhu L. Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. Comput Math Methods Med. 2022 May 21;2022:9765884. doi: 10.1155/2022/9765884. PMID: 35637842; PMCID: PMC9148243. 10: Barman HA, Tanyolaç S, Dogan O, Bal E, Atıcı A, Özyıldırım S, Yiğit Z. Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Clin Drug Investig. 2022 May 30. doi: 10.1007/s40261-022-01161-7. Epub ahead of print. PMID: 35635714. 11: Zhou S, Wang X, Xu H, Li J, Zhang L, Li H. Fabry disease with acute myocardial infarction, left ventricular thrombosis, and pericardial effusion: A case report. Medicine (Baltimore). 2022 May 27;101(21):e29427. doi: 10.1097/MD.0000000000029427. PMID: 35623077. 12: Matarneh AS, Hailan YMA, Abdul Karim S, Al Kuwari MA, Dabdoob WA. Endomyocardial fibrosis in a non-tropical patient who presented with chest pain mimicking ACS and left ventricular thrombus, case report. Clin Case Rep. 2022 May 23;10(5):e05021. doi: 10.1002/ccr3.5021. PMID: 35620258; PMCID: PMC9125399. 13: Liu S, Yin B, Wu B, Fan Z. Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta-analysis. Exp Ther Med. 2022 Jun;23(6):406. doi: 10.3892/etm.2022.11333. Epub 2022 Apr 21. PMID: 35619630; PMCID: PMC9115635. 14: Ishihara S, Hiramitsu S, Kanaoka K, Taki M, Nakagawa H, Ueda T, Seno A, Nishida T, Onoue K, Soeda T, Ohtani T, Watanabe M, Kawakami R, Sakata Y, Kario K, Saito Y. New Conversion Formula Between B-Type Natriuretic Peptide and N-Terminal-Pro-B-Type Natriuretic Peptide　- Analysis From a Multicenter Study. Circ J. 2022 May 25. doi: 10.1253/circj.CJ-22-0032. Epub ahead of print. PMID: 35613887. 15: Gupta R, Lin M, Maitz T, Egeler DJ, Sood A, Aronow WS, Rajeswaran Y, Ahnert AM, Vyas AV, Frishman WH, Lanier GM. Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator For Use in Patients with Heart Failure. Cardiol Rev. 2022 Jan 21. doi: 10.1097/CRD.0000000000000431. Epub ahead of print. PMID: 35609251. 16: Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ, de la Espriella R, Miñana G, Mezcua AR, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Górriz JL, Baýes-Genís A, Núñez J; DAPA-VO2 Investigators (see Appendix). Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial. Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2560. Epub ahead of print. PMID: 35604416. 17: Marin S, Godet I, Nidadavolu LS, Tian J, Dickinson LE, Walston JD, Gilkes DM, Abadir PM. Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells. Exp Gerontol. 2022 May 19;165:111835. doi: 10.1016/j.exger.2022.111835. Epub ahead of print. PMID: 35598697. 18: Zhang Y, Yuan M, Suo Y, Yang Q, Shao S, Li Y, Wang Y, Bao Q, Liu T, Li G. Angiotensin Receptor-Neprilysin Inhibitor Attenuates Cardiac Hypertrophy and Improves Diastolic Dysfunction in A Mouse Model of Heart Failure with Preserved Ejection Fraction. Clin Exp Pharmacol Physiol. 2022 May 20. doi: 10.1111/1440-1681.13672. Epub ahead of print. PMID: 35596518. 19: Kober G, Robaldo L, Paschke A. Modeling Medical Guidelines by Prova and SHACL Accessing FHIR/RDF. Use Case: The Medical ABCDE Approach. Stud Health Technol Inform. 2022 May 16;293:59-66. doi: 10.3233/SHTI220348. PMID: 35592961. 20: Codina P, Domingo M, Barceló E, Gastelurrutia P, Casquete D, Vila J, Abdul- Jawad Altisent O, Spitaleri G, Cediel G, Santiago-Vacas E, Zamora E, Ruiz-Cueto M, Santesmases J, de la Espriella R, Pascual-Figal DA, Nuñez J, Lupón J, Bayes- Genis A. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail. 2022 May 19. doi: 10.1002/ehf2.13952. Epub ahead of print. PMID: 35588235.